A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Public ClinicalTrials.gov record NCT06952699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Narcolepsy Without Cataplexy (NT2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with NT2 tolerate it. Researchers also want to find out if TAK-360 can help people with NT2 stay awake and determine the right dosage needed to do that. Participants will be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo in the treatment period. The placebo is a pill that looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.
Study identification
- NCT ID
- NCT06952699
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2025
- Primary completion
- Nov 29, 2026
- Completion
- Nov 29, 2026
- Last update posted
- Aug 19, 2026
2025 – 2026
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Takeda Site 36 | Auburn | Alabama | 36832 | Recruiting |
| Takeda Site 39 | Chandler | Arizona | 85224 | Withdrawn |
| Takeda Site 40 | Chula Vista | California | 91910 | Recruiting |
| Takeda Site 14 | Redwood City | California | 94063-3132 | Recruiting |
| Takeda Site 10 | Santa Ana | California | 92705-8519 | Recruiting |
| Takeda Site 1 | Colorado Springs | Colorado | 80918-3408 | Recruiting |
| Takeda Site 48 | Bradenton | Florida | 34209 | Recruiting |
| Takeda Site 13 | Brandon | Florida | 33511-5719 | Recruiting |
| Takeda Site 46 | Jacksonville | Florida | 32209 | Recruiting |
| Takeda Site 44 | Miami | Florida | 33155 | Recruiting |
| Takeda Site 35 | Miami | Florida | 33176 | Recruiting |
| Takeda Site 3 | Orlando | Florida | 32803-1468 | Recruiting |
| Takeda Site 33 | Orlando | Florida | 32807 | Recruiting |
| Takeda Site 32 | Atlanta | Georgia | 30328 | Recruiting |
| Takeda Site 49 | Bowie | Maryland | 20715 | Recruiting |
| Takeda Site 50 | Lansing | Michigan | 48911 | Recruiting |
| Takeda Site 34 | Lathrup Village | Michigan | 48076 | Recruiting |
| Takeda Site 4 | St Louis | Missouri | 63123-6968 | Recruiting |
| Takeda Site 37 | Middletown | New Jersey | 07748 | Recruiting |
| Takeda Site 8 | Denver | North Carolina | 28037 | Recruiting |
| Takeda Site 6 | Huntersville | North Carolina | 28078-5082 | Recruiting |
| Takeda Site 41 | Winston-Salem | North Carolina | 27103 | Recruiting |
| Takeda Site 5 | Cincinnati | Ohio | 45245-4500 | Recruiting |
| Takeda Site 45 | Cleveland | Ohio | 44106 | Recruiting |
| Takeda Site 2 | Columbia | South Carolina | 29201-2923 | Recruiting |
| Takeda Site 38 | Austin | Texas | 78731 | Recruiting |
| Takeda Site 43 | Dallas | Texas | 75235 | Withdrawn |
| Takeda Site 42 | El Paso | Texas | 79912 | Recruiting |
| Takeda Site 47 | Mansfield | Texas | 76063 | Withdrawn |
| Takeda Site 7 | San Antonio | Texas | 78229-4849 | Recruiting |
| Takeda Site 11 | Norfolk | Virginia | 23510-1021 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06952699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06952699 live on ClinicalTrials.gov.